Science news

PAKENERGY EXPANDS LEADERSHIP TEAM WITH KEY HIRES & ANNOUNCES NEW DALLAS LOCATION

DALLAS, Oct. 17, 2023 /PRNewswire/ -- PakEnergy, LLC (PakEnergy) a leading provider of powerful cloud-based software solutions for the oil and gas industry, announced...

HUMAN APPEAL RAMPS UP RELIEF EFFORTS TO "FORGOTTEN" EARTHQUAKE IN AFGHANISTAN

MANCHESTER, England, Oct. 17, 2023 /PRNewswire/ -- Human Appeal, one for the UK's fastest growing humanitarian charities, announced it is increasing its relief efforts...

Shaping the Future: Sungrow and LONGi Join Forces for C&I Solar Leadership Seminar in Dubai

DUBAI, UAE, Oct. 17, 2023 /PRNewswire/ -- Sungrow, the global leading inverter and energy storage system supplier, collaborated with LONGi for a groundbreaking joint seminar scheduled...

Plug In America Announces 2023 Drive Electric Award Honorees

The electric vehicle advocacy group is celebrating 15 individuals and organizations for their dedication and leadership in the electric vehicle movement on Nov. 9,...

Pieper Veterinary Partners with Portland Veterinary Emergency and Specialty Care Hospital in Portland Maine

MIDDLETOWN, Conn., Oct. 16, 2023 /PRNewswire/ -- Pieper Veterinary, a Connecticut-based family of primary, specialty, and emergency care veterinary hospitals, is excited to announce they have...

While Medication May Offer Relief, Christ Offers True and Lasting Peace

Xulon Press presents the answer to debilitating fear and anxiety. KNIFE RIVER, Minn., Oct. 16, 2023 /PRNewswire-PRWeb/ -- Author Theresa Ellison writes of the power...

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO, Oct. 15, 2023 /PRNewswire/ -- Astellas...

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have...

Latest articles